Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Neovasc Announces Second Quarter 2018 Financial Results Conference Call and Webcast

Canada NewsWire

NASDAQ, TSX: NVCN

VANCOUVER, Aug. 2, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the quarter and six months ended June 30, 2018 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, August 8, 2018.

Conference Call & Webcast


Wednesday, August 8th @ 4:30pm Eastern Time


Domestic:

888-254-3590

International:  

323-994-2093

Passcode:  

9226007

Webcast:

http://public.viavid.com/index.php?id=130206



Replays available through August 22nd:


Domestic:

844-512-2921

International:

412-317-6671

Conference ID:

9226007

                                                              

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™ (the "Tiara"), for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.

SOURCE Neovasc Inc.

View original content: http://www.newswire.ca/en/releases/archive/August2018/02/c1245.html



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today